FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma By Ogkologos - January 31, 2025 254 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CK-301-101 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... April 23, 2019 Genetic Mechanisms Identified for Acquired Resistance to Non-Covalent BTK Inhibitors March 28, 2022 Boosting Dendritic Cells Helps the Immune System Find Pancreatic Cancer April 28, 2020 Integrating Geriatric Assessment into Cancer Care: A Conversation with Dr. Supriya... September 11, 2018 Load more HOT NEWS Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer Talazoparib Plus Enzalutamide Improves rPFS in First-Line Treatment for Patients with... FDA Approves Belzutifan for Advanced Renal Cell Carcinoma FDA Approves Capivasertib with Fulvestrant for Breast Cancer
